: Atopic dermatitis (AD) is a chronic inflammatory skin disease with a prevalence of about 2%-10% in the adult.Cyclosporin is a traditional immunosuppressive drug efficacious for treating AD, but its use is limited by several adverse event. Dupilumab is a monoclonal antibody blocking the effects of both of interleukin (IL)-4 and IL-13, pivotal cytokines in the pathogenesis of atopic diseases.For chronic conditions, such as AD, the efficacy and safety of a drug can be evaluated by drug survival (DS) analysis which gives a reflection of daily practice by evaluating the time from initiation to discontinuation of therapy.This study provides a comparative survival analysis between the only 2 drugs approved in Italy for the treatment of moderate-to-severe AD, cyclospoorin and dupilumab.

Drug survival analysis of dupilumab and cyclosporin in patients with atopic dermatitis: a multicentre study / Napolitano, Maddalena; Mariano, Maria; Cristaudo, Antonio; Dastoli, Stefano; Di Guida, Adriana; De Lucia, Mario; Guerrasio, Gianluca; Nisticò, Steven Paul; Passante, Maria; Pigliacelli, Flavia; Fabbrocini, Gabriella; Patruno, Cataldo. - In: THE JOURNAL OF DERMATOLOGICAL TREATMENT. - ISSN 0954-6634. - (2022), pp. 1-7-7. [10.1080/09546634.2022.2067818]

Drug survival analysis of dupilumab and cyclosporin in patients with atopic dermatitis: a multicentre study

Napolitano, Maddalena;Di Guida, Adriana;De Lucia, Mario;Guerrasio, Gianluca;Fabbrocini, Gabriella;
2022

Abstract

: Atopic dermatitis (AD) is a chronic inflammatory skin disease with a prevalence of about 2%-10% in the adult.Cyclosporin is a traditional immunosuppressive drug efficacious for treating AD, but its use is limited by several adverse event. Dupilumab is a monoclonal antibody blocking the effects of both of interleukin (IL)-4 and IL-13, pivotal cytokines in the pathogenesis of atopic diseases.For chronic conditions, such as AD, the efficacy and safety of a drug can be evaluated by drug survival (DS) analysis which gives a reflection of daily practice by evaluating the time from initiation to discontinuation of therapy.This study provides a comparative survival analysis between the only 2 drugs approved in Italy for the treatment of moderate-to-severe AD, cyclospoorin and dupilumab.
2022
Drug survival analysis of dupilumab and cyclosporin in patients with atopic dermatitis: a multicentre study / Napolitano, Maddalena; Mariano, Maria; Cristaudo, Antonio; Dastoli, Stefano; Di Guida, Adriana; De Lucia, Mario; Guerrasio, Gianluca; Nisticò, Steven Paul; Passante, Maria; Pigliacelli, Flavia; Fabbrocini, Gabriella; Patruno, Cataldo. - In: THE JOURNAL OF DERMATOLOGICAL TREATMENT. - ISSN 0954-6634. - (2022), pp. 1-7-7. [10.1080/09546634.2022.2067818]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/884041
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 3
social impact